SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Quantum Cyber N.V. (QUCY) — Jun 12, 2026

Quantum Cyber N.V.
Date: June 12, 2026 · CIK: 0001874252 · Accession: 0000000000-26-005920

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-296480

Date
June 12, 2026
Author
Division of
Form
UPLOAD
Company
Quantum Cyber N.V.

Letter

Re: Quantum Cyber N.V. Registration Statement on Form S-3 Filed June 4, 2026 File No. 333-296480 Dear David Lazar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions.

June 12, 2026

David Lazar Chief Executive Officer and Director Quantum Cyber N.V. 30 Rockefeller Plaza, 26th Floor New York, NY 10112

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Alla Digilova, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 12, 2026

David Lazar
Chief Executive Officer and Director
Quantum Cyber N.V.
30 Rockefeller Plaza, 26th Floor
New York, NY 10112

 Re: Quantum Cyber N.V.
 Registration Statement on Form S-3
 Filed June 4, 2026
 File No. 333-296480
Dear David Lazar:
 This is to advise you that we have not reviewed and will not review your
registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Alla Digilova, Esq.
</TEXT>
</DOCUMENT>